Comparison between subcutaneous and intravenous interleukin-2 treatment in HIV disease

Journal of Internal Medicine

Volumn 244, Issue 3, 1998, Pages 235-240

  Witzke, O ^a   Winterhagen, T ^a   Reinhardt, W ^a   Heemann, U ^a   Grosse Wilde, H ^a   Kreuzfelder, E ^a   Roggendorf, M ^a   Philipp, T ^a,b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

CD4 lymphocytes; HIV infection; Interleukin 2

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INDINAVIR; PROTEINASE INHIBITOR; RECOMBINANT INTERLEUKIN 2; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MALAISE; MALE; MYALGIA; PRIORITY JOURNAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0031868999     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1998.00365.x     Document Type: Article

References (16)

1. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Eng J Med 1996; 334: 1011-17.
2. D'Aquila Hughes MD, Johnson VA, Fischl MA, Sommadossi JP, Liou SH et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HTV-1 infection. Ann Intern Med 1996; 124: 1019-30.
3. rd Conference on Retroviruses and Opportunistic Infections. Washington DC, January 1996 (abstract 175).
4. Mosmann TR. Cytokine patterns during the progression to AIDS. Science 1994; 265: 193.
5. Smith KA. Interleukin-2: inception, impact and implications. Science 1988; 240: 1169.
6. Lewis DE, Tang DS, Adu-Oppong A, Schober W, Rodgers JR. Anergy and apoptosis in CD8 and T-cells from HIV-infected persons. J Immunol 1994; 153: 412.
7. Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT, Falloon J et al. Increases in CD4-T-lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 1995; 332: 567-75.
8. Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT, Walker RE et al. Controlled trial of interleukin-2-infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996; 335: 1350-55.
9. Teppler H, Kaplan G, Smith K, Montana AL, Meyn P, Cohn ZA. Efficacy of low doses of polyethylene glxycol derivate of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. J Infect Dis 1993; 167: 291-98.
10. Lane HC, Siegel JP, Rook AH. Use of interleukin-2 in patients with acquired immunodeficiency syndrome. J Biol Response Modif 1984; 3: 512-16.
11. Schnittmann SM, Vogel S, Baseler M, Lane HC, Davey RT. A phase I study of interferon-alpha 2b in combination with interleukin-2 in patients with human immunodeficiency virus infection. J Infect Dis 1994; 169: 981-89.
12. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzales C, McMahon EA et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-39.
13. Kelleher AD, Carr A, Zaunders J, Cooper CA. Alterations in the immune response of human immunodeficiency virus (HIV) infected subjects treated with an HIV specific protease inhibitor, ritonavir. J Infect Dis 1996; 173: 321-29.
14. Kitchen VS, Skinner C, Ariyodhi K, Lane EA, Duncan IB, Burckhardt I et al. Safety and activity of saquinavir in HIV-infection. Lancet 1995; 345: 952-5.
15. Danner SA, Carr A, Leonard JM, Lehmann LM, Gudiol F, Gonzales I et al. A short-term study of the safety, pharmakokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528-33.
16. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL. A 24-week open label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996; 10: 485-92.